• That could represent further problems for Eyetech, which, along with Pfizer, already sells a treatment called Macugen for the disease--age-related macular degeneration (AMD).

    FORBES: Magazine Article

  • Eyetech shares soared last year based on the success of Macugen, a treatment for age-related macular degeneration (AMD), a leading cause of blindness.

    FORBES: OSI Chief Explains $935 Million Eyetech Buy

  • That could represent further problems for Eyetech (nasdaq: EYET - news - people ), which, along with Pfizer (nyse: PFE - news - people ), already sells a treatment called Macugen for the disease--age-related macular degeneration (AMD).

    FORBES: More Eye-Opening Data From Genentech

  • Two breakthrough drugs from Genentech offer hope for patients with the more severe "wet" form (which is more common in Asia than in the U.S.) of age-related macular degeneration, or AMD.

    FORBES: Magazine Article

  • Two breakthrough drugs from Genentech (nyse: DNA - news - people ) offer hope for patients with the more severe "wet" form of age-related macular degeneration, or AMD.

    FORBES: Banishing Blind Spots

  • Two breakthrough drugs from Genentech (nyse: DNA - news - people ) offer hope for patients with the more severe "wet" form (which is more common in Asia than in the U.S.) of age-related macular degeneration, or AMD.

    FORBES: Banishing Blind Spots

  • It is now focused on seeking treatments for major eye diseases, including Wet AMD, or age-related macular degeneration.

    FORBES: Teva Chairman Continues To Seek Undervalued Biopharmaceuticals

$firstVoiceSent
- 来自原声例句
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定
小调查
请问您想要如何调整此模块?

感谢您的反馈,我们会尽快进行适当修改!
进来说说原因吧 确定